Resistance to PARP inhibitors was obtained by silencing schlafen 11 (SLFN11) using CRISPR/Cas9 technology in patient-derived xenograft model of small-cell lung cancer (SCLC) (Lok et al., 2017). The gene discussed is SLFN11; the disease is small cell lung carcinoma.